Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends
Metabolomics is emerging as a powerful systems biology approach for improving preclinical drug safety assessment. This review discusses current applications and future trends of metabolomics in toxicology and drug development. Metabolomics can elucidate adverse outcome pathways by detecting endogeno...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/14/2/98 |
| _version_ | 1797297565756030976 |
|---|---|
| author | Fenna Sillé Thomas Hartung |
| author_facet | Fenna Sillé Thomas Hartung |
| author_sort | Fenna Sillé |
| collection | DOAJ |
| description | Metabolomics is emerging as a powerful systems biology approach for improving preclinical drug safety assessment. This review discusses current applications and future trends of metabolomics in toxicology and drug development. Metabolomics can elucidate adverse outcome pathways by detecting endogenous biochemical alterations underlying toxicity mechanisms. Furthermore, metabolomics enables better characterization of human environmental exposures and their influence on disease pathogenesis. Metabolomics approaches are being increasingly incorporated into toxicology studies and safety pharmacology evaluations to gain mechanistic insights and identify early biomarkers of toxicity. However, realizing the full potential of metabolomics in regulatory decision making requires a robust demonstration of reliability through quality assurance practices, reference materials, and interlaboratory studies. Overall, metabolomics shows great promise in strengthening the mechanistic understanding of toxicity, enhancing routine safety screening, and transforming exposure and risk assessment paradigms. Integration of metabolomics with computational, in vitro, and personalized medicine innovations will shape future applications in predictive toxicology. |
| first_indexed | 2024-03-07T22:22:11Z |
| format | Article |
| id | doaj.art-c9bd2b72aad5430596dd703a1e270ced |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-07T22:22:11Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-c9bd2b72aad5430596dd703a1e270ced2024-02-23T15:27:00ZengMDPI AGMetabolites2218-19892024-01-011429810.3390/metabo14020098Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future TrendsFenna Sillé0Thomas Hartung1Center for Alternatives to Animal Testing (CAAT), Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health and Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21205, USACenter for Alternatives to Animal Testing (CAAT), Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health and Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21205, USAMetabolomics is emerging as a powerful systems biology approach for improving preclinical drug safety assessment. This review discusses current applications and future trends of metabolomics in toxicology and drug development. Metabolomics can elucidate adverse outcome pathways by detecting endogenous biochemical alterations underlying toxicity mechanisms. Furthermore, metabolomics enables better characterization of human environmental exposures and their influence on disease pathogenesis. Metabolomics approaches are being increasingly incorporated into toxicology studies and safety pharmacology evaluations to gain mechanistic insights and identify early biomarkers of toxicity. However, realizing the full potential of metabolomics in regulatory decision making requires a robust demonstration of reliability through quality assurance practices, reference materials, and interlaboratory studies. Overall, metabolomics shows great promise in strengthening the mechanistic understanding of toxicity, enhancing routine safety screening, and transforming exposure and risk assessment paradigms. Integration of metabolomics with computational, in vitro, and personalized medicine innovations will shape future applications in predictive toxicology.https://www.mdpi.com/2218-1989/14/2/98metabolomicstoxicitysafetydrug developmentadverse outcome pathways |
| spellingShingle | Fenna Sillé Thomas Hartung Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends Metabolites metabolomics toxicity safety drug development adverse outcome pathways |
| title | Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends |
| title_full | Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends |
| title_fullStr | Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends |
| title_full_unstemmed | Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends |
| title_short | Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends |
| title_sort | metabolomics in preclinical drug safety assessment current status and future trends |
| topic | metabolomics toxicity safety drug development adverse outcome pathways |
| url | https://www.mdpi.com/2218-1989/14/2/98 |
| work_keys_str_mv | AT fennasille metabolomicsinpreclinicaldrugsafetyassessmentcurrentstatusandfuturetrends AT thomashartung metabolomicsinpreclinicaldrugsafetyassessmentcurrentstatusandfuturetrends |